Dr. Klute is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
42nd And Emile
Omaha, NE 68198
Summary
- Dr. Kelsey Klute is an oncologist in Omaha, NE and is affiliated with multiple hospitals in the area, including Nebraska Medical Center (UNMC) and Nebraska Medicine - Nebraska Medical Center. She received her medical degree from University of North Dakota School of Medicine and Health Sciences and has been in practice 7 years. She specializes in hematologic oncology.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2013 - 2016
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2010 - 2013
University of North Dakota School of Medicine and Health SciencesClass of 2010
Certifications & Licensure
NE State Medical License 2016 - 2026
NY State Medical License 2013 - 2016
MO State Medical License Active through 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2021 Jun 16
- Pancreatic Cancer Early Detection Consortium Start of enrollment: 2020 Sep 18
Roles: Principal Investigator
Publications & Presentations
PubMed
- 143 citationsTreatment of Metastatic Colorectal Cancer: ASCO Guideline.Van K Morris, Erin B Kennedy, Nancy N Baxter, Al B Benson 3rd, Andrea Cercek
Journal of Clinical Oncology. 2023-01-20 - 588 citationsPancreatic adenocarcinoma, Version 2.2021Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary, Stephen W. Behrman, Al B. Benson
Journal of the National Comprehensive Cancer Network. 2021-04-01 - 11 citationsDisruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.Parthasarathy Seshacharyulu, Sushanta Halder, Ramakrishna Nimmakayala, Satyanarayana Rachagani, Sanjib Chaudhary
Ebiomedicine. 2022-01-01
Lectures
- Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- #earlydetection: Leveraging social media to recruit individuals at increased-risk of pancreas cancer for an early detection study.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical TrialAugust 14th, 2024- RenovoRx Expands Enrollment in TIGeR-PaC Pivotal TrialAugust 14th, 2024
- University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical TrialJune 26th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
